BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
MDM2
,
Apoptosis
,
Pseudomonas infection
,
Liver
,
Neocentromeres
,
Aspirin
,
rs2230926
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
TiPARP
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Eosinophil of peripheral blood
Adrenal gland cortex
T Lymphocyte (CD8+) of peripheral blood
Vena cava
Peritoneum
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Traumatic injury
Shock
Weightlessness
Ischemia
Finding related to sleep
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
flavopiridol
Tetrachlorodibenzodioxin
phenanthridone
Apazone
CGP 60474
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Zfx
NANOS1
KSR2
SRSF2
SRF
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Structurally distinct PARP7 inhibitors provide new insights into the function of PARP7 in regulating…
Identification of PARP-7 substrates reveals a role for MARylation in microtubule control in ovarian …
Post-Transcriptional Regulation of PARP7 Protein Stability Is Controlled by Androgen Signaling.
PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dep…
Chemical genetics and proteome-wide site mapping reveal cysteine MARylation by PARP-7 on immune-rele…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ